Evolus prices public offering of 3.55M shares at $14.07/share; net proceeds ~$46.9M

Evolus, Inc.

Underwriters Leerink and Stifel purchase 3,554,000 shares at $13.2258/share; option for 533,100 more.
Estimated net proceeds of $46.9M (up to $54.1M if option exercised) to fund Jeuveau growth, Evolysse launch.
Lock-up agreements restrict insider sales for 60 days from March 11, 2024.
Offering closed on March 13, 2024; proceeds also for potential business development.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Evolus, Inc. entered into Underwriting Agreement with Leerink Partners, LLC and Stifel, Nicolaus & Company, Incorporated as representatives of the underwriters named in Schedule A valued at approximately $46.9 million (effective 2024-03-11).

Action: entry
Agreement: underwriting
Counterparty: Leerink Partners, LLC and Stifel, Nicolaus & Company, Incorporated as representatives of the underwriters named in Schedule A
Value: approximately $46.9 million
Effective: 2024-03-11

Exact text from the filing

On March 11, 2024, Evolus, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners, LLC and Stifel, Nicolaus & Company, Incorporated as representatives of the underwriters named in Schedule A thereto (together, the “Underwriters”), in connection with the underwritten public offering, issuance and sale by the Company (the “Offering”) of 3,554,000 shares (the “Firm Shares”) of the Company’s common stock, par value $0.00001 per share (the “Common Stock”).

View on SEC.gov

565 material agreements filed in the last 30 days. Browse all material agreements →

Evolus, Inc. filing history →

Source: SEC EDGAR

accession 0001570562-24-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.